Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF MUTATION
BRAF MUTATION - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between BRAF mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 39 had wildtype BRAF and 5 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to irinotecan-based first-line therapy than patients with wildtype BRAF (Median PFS: 3.5 and 12.8 months, respectively; p = .006).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6304
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/399
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Irinotecan
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 19603024
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Irinotecan | Resitance or Non-Reponse | true |